SBI Holdings Of Japan To License Antibodies To AstraZeneca
This article was originally published in PharmAsia News
Executive Summary
Japan's SBI Holdings plans to sell its antibody-drug rights to U.K.-based AstraZeneca to develop and market. SBI Holdings is a venture capital firm that owns SBI Biotech, and expects to earn about $94.7 million from the drug. AstraZeneca's Medimmune is to conduct the clinical trials on drugs for lupus and other autoimmune disorders. SBI hopes to take advantage of AstraZeneca's global presence to get the drug to market. (Click here for more - a subscription may be required
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.